- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pearson on the Education of Value Frameworks Among Physicians
While discussion of value frameworks has grown in academic and policy meeting settings, physician education on the subject is still in its very early stages, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.
While discussion of value frameworks has grown in academic and policy meeting settings, physician education on the subject is still in its very early stages, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.
Transcript (slightly modified)
How are physicians being educated on the multiple value framework tools being developed?
I think that we are in the early days around the development and the application of value frameworks in a variety of different areas. For clinicians, to me, there are 2 important things. They ought to be part of the conversation around value. They ought to do it through their societies, but also as clinicians, even as individuals.
I think to have a good understanding of the ways that patients, payers, and policy makers think about value so that, again, they can contribute to that discussion. So I think that how they’re being educated now is pretty haphazard. I think this is continuing to grow in importance at academic meetings and at policy meetings, but the average clinician really hasn’t heard much about value frameworks yet. So we’ve a lot of work to do.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
